reports
An increasingly favourable environment allows PHARMARON BEIJING to imp...
The independent financial analyst theScreener just upgraded the general evaluation of PHARMARON BEIJING (CN), a company active in the Biotechnology industry. As regards its fundamental valuation, the title confirms its rating of 2 out of 4 stars while its market behaviour remains as risky. theScreener believes, however, that a more enabling environment allows the title to increase its general evaluation to Neutral. As of the analysis date March 18, 2022, the closing price was HKD 83.35 and its e...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.